Updating results

251 results for breast cancer Sort: Relevance | Date

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164)

recommendations on familial (inherited) breast cancer and related risks for people with a family history of...

Clinical guideline Published June 2013 Last updated March 2017

Breast cancer

Everything NICE has produced on the topic of breast cancer. Includes related guidelines, NICE Pathways, quality standards...

Advanced breast cancer

Everything NICE has said on diagnosing and treating advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated January 2018

Advanced breast cancer: diagnosis and treatment (CG81)

Evidence-based recommendations on diagnosing and treating advanced (stage 4) breast cancer (invasive adenocarcinoma) for...

Clinical guideline Published February 2009 Last updated August 2017

Familial breast cancer

Everything NICE has said on assessing and managing familial breast cancer and related risks in people with a family history...

NICE Pathway Published October 2011 Last updated September 2017

Early and locally advanced breast cancer

NICE has said on diagnosing and treating early and locally advanced breast cancer in an interactive flowchart

NICE Pathway Published May 2011 Last updated January 2018

Early and locally advanced breast cancer: diagnosis and treatment (CG80)

diagnosing and treating early and locally advanced (stage 1 & 2) breast cancer (adenocarcinoma) for women and men

Clinical guideline Published February 2009 Last updated March 2017

Gemcitabine for the treatment of metastatic breast cancer (TA116)

Evidence-based recommendations on gemcitabine (Gemzar) for treating metastatic breast cancer

Technology appraisal guidance Published January 2007

Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)

Evidence-based recommendations on breast reconstruction using lipomodelling after breast cancer treatment

Interventional procedures guidance Published January 2012

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)

Evidence-based recommendations on pertuzumab (Perjeta) for HER2-positive breast cancer in adults

Technology appraisal guidance Published December 2016

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine...

Technology appraisal guidance Published December 2016

Interstitial laser therapy for breast cancer (IPG89)

Evidence-based recommendations on interstitial laser therapy for treating breast cancer

Interventional procedures guidance Published September 2004

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel) [ID523]

In development [GID-TAG322] Expected publication date: 07 March 2018

Technology appraisal guidance In development

Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

endoscopic mastectomy and endoscopic wide local excision for breast cancer (keyhole removal of breast tissue)

Interventional procedures guidance Published April 2009

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

trastuzumab emtansine (Kadcyla) for treating advanced HER2-positive breast cancer that has been treated before

Technology appraisal guidance Published July 2017 Last updated November 2017

Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer

Interventional procedures guidance Published December 2005

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)

recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of...

Technology appraisal guidance Published December 2016

Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

recommendations on brachytherapy as the only type of adjuvant radiotherapy for breast cancer after local excision

Interventional procedures guidance Published July 2008

Improving outcomes in breast cancer (CSG1)

Evidence-based recommendations on improving outcomes in breast cancer

Cancer service guideline Published August 2002

ESNM13: Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab

Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and...

Evidence summary Published March 2013

NICE consults on updated recommendations for the treatment and care of people with early breast cancer

advanced breast cancer calls for extended hormonal therapy for some women after they’ve taken tamoxifen in order to reduce...

News Published January 2018

MIB111: L-Dex U400 for lymphoedema after breast cancer treatment

Advice on the use of L-Dex U400 for lymphoedema (lymphedema) after breast cancer treatment to aid local decision-making

Medtech innovation briefing Published July 2017

ES15: Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates

for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

MIB76: Axxent electronic brachytherapy system for early stage breast cancer

the Axxent electronic brachytherapy system for treating early stage breast cancer to aid local decision-making

Medtech innovation briefing Published August 2016

MIB135: MammaTyper in vitro diagnostic test for determining breast cancer subtypes

on the use of the MammaTyper in vitro diagnostic test for determining breast cancer subtypes to aid local decision-making

Medtech innovation briefing Published January 2018

MIB44: EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence

EndoPredict gene expression profiling assay for assessing the risk of breast cancer recurrence to aid local decision-making

Medtech innovation briefing Published November 2015

MIB27: The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence

Prosigna gene expression profiling assay for assessing long-term risk of breast cancer recurrence to aid local...

Medtech innovation briefing Published March 2015

Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

recommendations on image-guided radiofrequency excision biopsy of breast lesions to test for breast cancer

Interventional procedures guidance Published July 2009

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Breast cancer - intensity modulated radiotherapy [ID16]

In development [GID-TAG390] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) - lapatinib [ID20]

In development [GID-TAG387] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

In development [GID-TAG403] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (brain metastases) - etirinotecan pegol [ID881]

In development [GID-TA10066] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]

In development [GID-TAG404] Expected publication date: TBC

Technology appraisal guidance In development

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]

In development [GID-TAG432] Expected publication date: TBC

Technology appraisal guidance In development